On this page
At a glance
Pemvidutide is a balanced (1:1) glucagon/GLP-1 dual receptor agonist given by weekly subcutaneous injection. It is not FDA-approved and is in Phase 2b development for MASH (fatty-liver disease with inflammation) by Altimmune. On January 5, 2026 the FDA granted it Breakthrough Therapy Designation for MASH — a development status, not an approval. New 48-week data from the Phase 2b IMPACT trial were presented at EASL 2026, showing meaningful improvements in fibrosis markers, lipids, weight, and blood pressure.
Translational DIO-NASH mouse study (Nestor 2022, Scientific Reports) compared pemvidutide head-to-head with semaglutide and elafibranor, showing superior reductions in steatosis, inflammation, and fibrosis attributed to the glucagon receptor arm. Molecular design characterized in Nestor 2021 (Peptide Science).
Phase 1b MASLD study (n=94, peer-reviewed in J Hepatol), Phase 2 MOMENTUM obesity trial (n=391, topline), and Phase 2b IMPACT MASH trial (n=212). IMPACT 24-week results are peer-reviewed in The Lancet; 48-week data were presented at EASL 2026. No Phase 3 data yet. Not FDA-approved.
Tolerability has been favorable across trials: in IMPACT at 48 weeks, treatment discontinuation due to adverse events was roughly 1%, and GI events were predominantly mild-to-moderate and concentrated in the first 8 weeks. No long-term or post-marketing surveillance data exist.
How are these scores calculated?
Pemvidutide is an investigational drug -- it has not been approved by the FDA or any regulatory agency. What Breakthrough Therapy Designation means: it expedites FDA review and reflects promising early data, but it is not an approval and does not make the drug available. What that means for you: the Phase 2b data is encouraging, but Phase 3 has not begun, long-term safety is unknown, and pemvidutide is not available by prescription, at pharmacies, or through compounding.
New research, delivered clearly
When new studies publish or clinical trials report results, we'll break them down in plain language.
Quick facts
- Molecular weight
- ~3,873.4 Da
- Mechanism
- Balanced 1:1 GLP-1 / glucagon dual agonist
- Dosing
- Once-weekly subcutaneous (no titration)
- Developer
- Altimmune, Inc.
- FDA status
- Not approved (Phase 2b; Breakthrough Therapy for MASH)
- WADA status
- Monitoring Program (not prohibited)
Amino acid sequence
Not publicly disclosed
What is pemvidutide?
Pemvidutide (development code ALT-801) is a synthetic peptide that activates two metabolic-hormone receptors at once: GLP-1 (glucagon-like peptide-1) and glucagon.[8] What makes it distinctive is that it engages those two receptors in a balanced 1:1 ratio — the design hypothesis being that an even split maximizes weight loss and the direct liver benefits of glucagon while limiting the gastrointestinal intolerance that comes from leaning too hard on GLP-1.
It is being developed by Altimmune, a clinical-stage company in Gaithersburg, Maryland, primarily for MASH (metabolic dysfunction-associated steatohepatitis — fatty-liver disease that has progressed to inflammation and scarring), as well as obesity, alcohol use disorder, and alcohol-associated liver disease. The molecule incorporates a proprietary "EuPort" domain — a glycolipid/surfactant attachment that binds albumin and slows release, enabling once-weekly dosing without the gradual dose escalation that most incretin drugs require.[8]
Unlike a pure GLP-1 drug such as semaglutide, pemvidutide adds glucagon receptor agonism. Glucagon acts directly on the liver to burn fat and increases whole-body energy expenditure — which is why dual agonists like pemvidutide and survodutide have drawn so much attention specifically for liver disease.
Important: Pemvidutide is not FDA-approved and is not available by prescription, at pharmacies, or through compounding. It is only available through enrollment in clinical trials. Any commercial sale of pemvidutide is unauthorized.
How it works
In plain terms, pemvidutide mimics two hormones your body uses to manage appetite, blood sugar, and energy balance. The GLP-1 arm reduces appetite and helps regulate glucose; the glucagon arm tells the liver to break down stored fat and nudges the body to burn more energy. Together they are meant to reproduce the complementary effects of diet (eating less) and exercise (burning more).[7]
The "balanced 1:1" framing matters. Earlier dual agonists tended to favor one receptor over the other. Pemvidutide was deliberately tuned to a roughly even split, on the theory that this produces stronger weight loss and better metabolic control than a design biased toward either hormone.
Detailed mechanism (for advanced readers)
Pemvidutide is a balanced (1:1) GLP-1 / glucagon receptor dual agonist:[8]
GLP-1 receptor agonism:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Central appetite suppression via hypothalamic and brainstem GLP-1 receptors
- Delayed gastric emptying (contributes to satiety and to GI side effects)
- Drives the appetite/weight side of the "diet" analogy
Glucagon receptor agonism (the differentiator vs. pure GLP-1 drugs):
- Acts directly on the liver to promote hepatic lipid oxidation, reducing liver fat
- Increases whole-body energy expenditure (the "exercise" analogy)
- Associated in preclinical work with reductions in hepatic inflammation and fibrosis
- This is the component shared with survodutide and retatrutide, and absent from semaglutide and tirzepatide
Why "balanced" matters: Glucagon agonism alone can raise blood glucose; the GLP-1 arm offsets that, while glucagon adds energy expenditure and direct liver effects. Tuning the two to roughly 1:1 is intended to capture the upside of each while keeping glucose control intact.
The EuPort domain and dosing:
- A proprietary glycolipid/surfactant moiety conjugated to the peptide
- Provides near-quantitative but transient binding to serum albumin (estimated >99%), protecting the peptide from proteolysis and renal clearance
- Surfactant-like properties form micelles that slow entry into the bloodstream
- Net result: a serum half-life long enough for once-weekly dosing without dose titration
A note on identity: The full amino acid sequence of pemvidutide has not been publicly disclosed by Altimmune. Public chemistry databases list a molecular formula of C₁₈₂H₂₇₅N₃₉O₅₄ and a molecular weight of approximately 3,873 Da. We report what is disclosed and flag the rest as unknown rather than estimate it.
What the research says
Pemvidutide's liver and metabolic data are genuinely promising — and the FDA's Breakthrough Therapy Designation reflects that. But the evidence base is still Phase 2b: the pivotal IMPACT trial met one of its two co-primary endpoints at 24 weeks and missed the other, Phase 3 has not started, and there is no long-term safety data. Encouraging is not the same as proven.
Research timeline
Pemvidutide has moved steadily from preclinical work toward a Phase 3 decision:
- 2021Preclinical
Molecule design published
Nestor et al. (Peptide Science) describe ALT-801 as a balanced 1:1 GLP-1/glucagon dual agonist built around the proprietary EuPort domain for albumin binding and weekly dosing.
- 2022Preclinical
Preclinical NASH proof of concept
Nestor et al. (Scientific Reports) report that ALT-801 outperformed semaglutide and elafibranor on steatosis, inflammation, and fibrosis in a biopsy-confirmed DIO-NASH mouse model — pointing to the glucagon arm's liver effects.
- 2023Human study
Phase 2 obesity data (MOMENTUM)
Topline results from the 48-week MOMENTUM obesity trial (n=391): up to 15.6% weight loss at 2.4 mg, with only 21.9% of weight lost coming from lean mass.
- 2025Human study
Phase 1b MASLD data published
Harrison et al. (Journal of Hepatology) report up to 68.5% liver-fat reduction at 1.8 mg over 12 weeks in MASLD (n=94), establishing the hepatic signal in humans.
- 2026Human study
Breakthrough Therapy + 48-week MASH data
January 5, 2026: FDA grants Breakthrough Therapy Designation for MASH (based on 24-week IMPACT data). May 28, 2026: 48-week IMPACT data at EASL 2026 show continued fibrosis-marker, lipid, weight, and blood-pressure improvements. PERFORMA Phase 3 planned to start in H2 2026.
Human clinical trials
Pemvidutide has been studied across three human programs with a combined enrollment of roughly 700 participants:
Phase 1b MASLD (Harrison 2025): A 12-week study (n=94) that first showed the hepatic effect — up to a 68.5% reduction in liver fat at 1.8 mg.[5]
Phase 2 MOMENTUM obesity (2023): A 48-week trial (n=391) establishing weight-loss efficacy and a favorable lean-mass-preservation profile.[6]
Phase 2b IMPACT MASH (2026): The pivotal trial in biopsy-confirmed F2/F3 MASH (n=212), randomized 1:2:2 to placebo, 1.2 mg, or 1.8 mg weekly for 48 weeks. The 24-week results are peer-reviewed in The Lancet; the 48-week data were presented at EASL 2026.[1][2]
Phase 1b: Pemvidutide for MASLD (Harrison 2025)
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Liver fat content reduced by 46.6% (1.2 mg), 68.5% (1.8 mg), and 57.1% (2.4 mg) vs. 4.4% placebo at 12 weeks. At 1.8 mg, 94.4% achieved a 30% reduction in liver fat and 55.6% reached normal liver fat (<5%). Accompanied by reductions in ALT and body weight.
MOMENTUM: Pemvidutide for obesity (Phase 2)
Obesity or overweight with a comorbidity (without diabetes)
Weight loss of 10.3% (1.2 mg), 11.2% (1.8 mg), and 15.6% (2.4 mg) vs. 2.2% placebo at 48 weeks, with the high-dose curve still descending at end of treatment. Only 21.9% of the weight lost was lean mass — a more favorable ratio than typically reported for incretin drugs.
IMPACT: MASH — 24-week results (Phase 2b, Lancet)
Biopsy-confirmed MASH with F2/F3 fibrosis (± diabetes)
Met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks; did NOT meet the co-primary endpoint of fibrosis improvement without worsening of MASH at this early timepoint. qFibrosis ≥1-stage regression at the 24-week biopsy: 68.6% (1.2 mg) and 54.5% (1.8 mg) vs. 29.6% placebo.
IMPACT: MASH — 48-week data (EASL 2026)
Biopsy-confirmed MASH with F2/F3 fibrosis (± diabetes)
Combined non-invasive fibrosis response (≥0.5 ELF reduction + ≥30% LSM reduction) at week 48: 27.8% (1.2 mg) and 32.4% (1.8 mg) vs. 3.2% placebo. At 1.8 mg: triglycerides −23.7%, total cholesterol −15.4%, weight loss 7.5% (no plateau), BMI −3.0 kg/m², waist −5.3 cm, SBP −4.0 mmHg, DBP −2.2 mmHg.
Where the evidence stands: The liver-fat and weight-loss signals are well-documented and partly peer-reviewed (Phase 1b in J Hepatol, IMPACT 24-week in The Lancet). The 48-week IMPACT data come from a conference presentation and company release, not yet a full peer-reviewed publication. Crucially, IMPACT is a Phase 2b trial — the confirmatory Phase 3 (PERFORMA) has not started. The evidence picture will look very different once Phase 3 reads out.
What the evidence shows
Pemvidutide has generated real excitement for liver disease specifically. Here's what the published and presented research actually supports:
Does pemvidutide resolve MASH (steatohepatitis)?
Partially. In Phase 2b IMPACT (n=212, F2/F3 MASH), pemvidutide met its primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks — but missed the co-primary endpoint of fibrosis improvement without worsening of MASH at that early timepoint. The 48-week data show continued improvement on non-invasive markers. This is a single Phase 2b trial; Phase 3 (PERFORMA) has not started.
Does pemvidutide reduce liver fibrosis?
Partially. At 24 weeks, qFibrosis (AI digital pathology) showed ≥1-stage regression in 68.6% (1.2 mg) and 54.5% (1.8 mg) vs. 29.6% placebo. At 48 weeks, the combined ELF + LSM non-invasive response was 27.8% (1.2 mg) and 32.4% (1.8 mg) vs. 3.2% placebo. Encouraging anti-fibrotic signals — but biopsy-based fibrosis improvement did not hit the IMPACT co-primary threshold at 24 weeks, and Phase 3 confirmation is pending.
Does pemvidutide reduce liver fat?
Yes. In the peer-reviewed Phase 1b MASLD study (n=94), liver fat fell by up to 68.5% at 1.8 mg over 12 weeks vs. 4.4% placebo, with 55.6% of the 1.8 mg group reaching normal liver fat. Preclinical DIO-NASH work attributes the effect largely to the glucagon receptor arm, which drives hepatic fat oxidation.
Does pemvidutide cause weight loss?
Yes. The Phase 2 MOMENTUM obesity trial (n=391) showed up to 15.6% weight loss at 2.4 mg over 48 weeks vs. 2.2% placebo, still descending at end of treatment, with only 21.9% of weight lost coming from lean mass. In the MASH population at lower doses, 48-week weight loss was 7.5% at 1.8 mg, also without plateau.
Does pemvidutide improve cardiometabolic risk factors?
Yes. In IMPACT at 48 weeks (1.8 mg), pemvidutide reduced triglycerides by 23.7%, total cholesterol by 15.4%, waist circumference by 5.3 cm, BMI by 3.0 kg/m², systolic BP by 4.0 mmHg, and diastolic BP by 2.2 mmHg vs. placebo. These are trial endpoints, not cardiovascular-outcome data.
Is pemvidutide more effective than approved GLP-1 drugs?
Unknown. Preclinically it outperformed semaglutide on liver endpoints, and its lean-mass-preservation looks favorable in cross-trial comparison. But there are no head-to-head human trials. Its peak obesity weight loss (~15.6%) is in a similar range to approved GLP-1 drugs, not clearly superior. Cross-trial comparisons are inherently unreliable.
Can you buy pemvidutide now?
No. Pemvidutide is not FDA-approved and is not available at pharmacies, by prescription, or through compounding. Breakthrough Therapy and Fast Track designations are development statuses, not approvals. The only legal route is clinical-trial enrollment. Any commercial sale is unauthorized.
Safety & side effects
What clinical trials show
Pemvidutide's safety profile is based on roughly 700 participants across Phase 1b, Phase 2, and Phase 2b trials. Across these studies, tolerability has been a relative strength for the program.
Gastrointestinal events (the most common side effects): As with the GLP-1 class, the dominant side effects are gastrointestinal. In IMPACT, GI adverse events were predominantly mild-to-moderate and concentrated in the first roughly 8 weeks of treatment.[2] A design goal of the balanced 1:1 ratio — and of starting at a therapeutic dose without titration — was to keep GI intolerance manageable.
Tolerability and discontinuation: At 48 weeks in IMPACT, treatment discontinuation due to adverse events was approximately 1% — a notably low figure, and one the company has highlighted as a differentiator.[2] In the MOMENTUM obesity trial, the company reported no imbalances in cardiac events or arrhythmias and no clinically meaningful increase in heart rate.[6]
Other safety considerations
- Glucagon-specific effects: Adding glucagon agonism is the novel element. Glucagon can raise blood glucose and heart rate; the balanced design is intended to offset the glucose effect with the GLP-1 arm. Long-term effects of chronic glucagon receptor stimulation are not yet characterized in humans.
- Lean mass loss: Expected with weight loss, but the reported ratio (only ~21.9% of weight lost from lean mass in MOMENTUM) is more favorable than typically reported for incretin drugs.
- Unknown long-term safety: The longest trials run 48 weeks. There is no multi-year data and no post-marketing surveillance, because the drug is not approved.
- Class-level warnings: GLP-1 receptor agonists carry warnings including a thyroid C-cell tumor concern (from rodent studies) and pancreatitis. Pemvidutide's specific risk has not been characterized in humans.
What we don't know about safety
There are important gaps in the pemvidutide safety data:
- No long-term (>48 week) data: Chronic-use safety is unknown.
- No post-marketing surveillance: All data comes from controlled clinical trials. Real-world patterns may differ.
- Glucagon receptor uncertainty: The long-term metabolic consequences of chronic glucagon receptor agonism — on hepatic glucose production, bone, and other systems — are not well understood.
- No thyroid C-cell or pancreatitis characterization in humans: These are class-level concerns that have not been specifically ruled in or out for pemvidutide.
- No pregnancy or drug-interaction data published.
- 48-week IMPACT data not yet peer-reviewed: The most complete dataset to date comes from a conference presentation and company release.
Legal & regulatory status
As of June 2026:
FDA status
Pemvidutide is not FDA-approved for any indication. It is an investigational drug in Phase 2b development.
- Breakthrough Therapy Designation (MASH): Granted January 5, 2026, based on 24-week IMPACT data. This designation expedites FDA development and review for serious conditions where early data suggest substantial improvement over existing options. It is a development status, not an approval — pemvidutide cannot be prescribed on the basis of this designation.[4]
- Fast Track designations: Granted for both MASH and alcohol use disorder — again, expedited-development statuses, not approvals.
- No approved pemvidutide product exists. It is not a component of any FDA-approved drug and has not been found safe and effective for any condition.[10]
- Next step: The PERFORMA Phase 3 MASH trial is planned to initiate in the second half of 2026.[2]
Other programs in development
- RECLAIM (alcohol use disorder): Topline data are expected in the third quarter of 2026.
- RESTORE (alcohol-associated liver disease): Enrollment completion is expected in the third quarter of 2026 — this is an enrollment milestone, not a data readout.
A note on designations: Breakthrough Therapy and Fast Track designations are easy to misread as a stamp of approval. They are not. They mean the FDA has agreed to work more closely and quickly with the developer because the early data are promising and the condition is serious. The drug still has to complete Phase 3 and pass full FDA review before it can be approved or prescribed.
How to access pemvidutide today
The only legal way to access pemvidutide is through enrollment in a clinical trial. Trial listings can be found at ClinicalTrials.gov by searching "pemvidutide" or "ALT-801."
Warning: Any website, pharmacy, or supplier offering pemvidutide for sale is operating outside regulatory boundaries. The drug has not been approved, cannot be legally prescribed, and cannot be legally compounded. "Research-grade" peptides sold online are unregulated and may not contain what they claim.
WADA / USADA status
Pemvidutide is not prohibited under the 2026 WADA Prohibited List. GLP-1 receptor agonists are on WADA's Monitoring Program rather than the Prohibited List, so their use by athletes is tracked but does not constitute an anti-doping violation. As a glucagon/GLP-1 dual agonist, pemvidutide is not currently prohibited, though WADA could reclassify the GLP-1 class in a future update.[9]
How pemvidutide compares
Pemvidutide's natural comparators are other glucagon-containing agonists in metabolic and liver development — especially survodutide (a GLP-1/glucagon dual agonist from Boehringer Ingelheim) and retatrutide (a triple GIP/GLP-1/glucagon agonist from Eli Lilly). No head-to-head trials exist, so the comparison below relies on cross-trial data, which has important limitations:
Pemvidutide
Not approved · Balanced GLP-1/glucagon agonist
Mechanism
GLP-1 + GCG (1:1)
Dosing
Weekly SC
Stage
Phase 2b
Compounding
Not available
Survodutide
Not approved · GLP-1/glucagon dual agonist
Mechanism
GLP-1 + GCG
Dosing
Weekly SC
Stage
Phase 3
Compounding
Not available
Retatrutide
Not approved · Triple GIP/GLP-1/glucagon agonist
Mechanism
GIP+GLP-1+GCG
Dosing
Weekly SC
Stage
Phase 3
Compounding
Not available
The key tradeoffs:
- Weight loss: Pemvidutide's peak obesity weight loss (~15.6%) is meaningful but lower than retatrutide's cross-trial figures (24-29%) and somewhat below survodutide's reported range. All three lack head-to-head data.[6]
- Liver focus: Pemvidutide's lead indication is MASH, where its glucagon-driven liver-fat reduction (up to 68.5%) and Breakthrough Therapy Designation are the headline. Survodutide is also strongly positioned in MASH.[5]
- Lean mass: Pemvidutide's reported lean-mass-preservation profile (only ~21.9% of weight lost from lean mass) is a distinguishing claim worth watching as larger datasets accrue.
- Development stage: Pemvidutide is the least advanced of the three (Phase 2b, with Phase 3 PERFORMA planned for H2 2026), while survodutide and retatrutide are in Phase 3.
- Availability: None of the three is FDA-approved. All are trial-only and cannot be compounded.
The bottom line: pemvidutide is an early-but-promising contender whose strongest case is in liver disease, where the glucagon arm and a favorable tolerability profile stand out. It is also the earliest-stage of its peer group, and its data is not yet confirmed by Phase 3.
Related content
Survodutide Profile
Boehringer Ingelheim's GLP-1/glucagon dual agonist, also in MASH development. The closest mechanistic comparator to pemvidutide.
PeptideRetatrutide Profile
Eli Lilly's triple GIP/GLP-1/glucagon agonist. Shares the glucagon arm that drives pemvidutide's liver-fat effects, with a third receptor added.
PeptideCagrilintide Profile
A long-acting amylin analog in metabolic development. Useful contrast: a different (amylin) mechanism for weight and metabolic control.
GuideWhat Are Peptides?
A foundational primer — helpful context for understanding pemvidutide's dual-agonist mechanism.
GuidePeptide vs. Small Molecule vs. Biologic
Where peptide drugs like pemvidutide sit relative to small molecules and biologics — and why that shapes how they are dosed and regulated.
ToolPeptide Tools Hub
Calculators and visualizers, including a half-life and accumulation plotter for weekly-dosed peptides like pemvidutide.
References
- [1]Noureddin M, Harrison SA, Suschak JJ, et al.. “Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.” Lancet. 2026. 407(10529):704-715 DOIRCT
Peer-reviewed 24-week Phase 2b IMPACT results. n=212, biopsy-confirmed F2/F3 MASH. Met primary endpoint of MASH resolution without worsening of fibrosis; did not meet co-primary fibrosis-improvement endpoint at 24 weeks.
- [2]Altimmune, Inc.. “Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026.” 2026. LinkRCT
Company news release (not peer-reviewed) for 48-week IMPACT data at EASL 2026. Combined ELF+LSM response 27.8% (1.2 mg) / 32.4% (1.8 mg) vs. 3.2% placebo. 1.8 mg: TG −23.7%, total cholesterol −15.4%, weight loss 7.5%, BMI −3.0 kg/m², waist −5.3 cm, SBP −4.0 / DBP −2.2 mmHg.
- [3]Altimmune, Inc.. “New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026.” 2026. LinkRCT
Company news release. qFibrosis (digital pathology) ≥1-stage regression at the 24-week biopsy: 68.6% (1.2 mg, p<0.001) and 54.5% (1.8 mg, p=0.002) vs. 29.6% placebo. qFibrosis figures are from 24 weeks, distinct from the 48-week non-invasive readout.
- [4]Altimmune, Inc.. “Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH.” 2026. LinkReview
Company news release dated January 5, 2026 announcing FDA Breakthrough Therapy Designation for MASH, based on 24-week IMPACT data. A development/review status, not an approval.
- [5]Harrison SA, Browne SK, Suschak JJ, et al.. “Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.” J Hepatol. 2025. 82(1):7-17 DOI PubMedRCT
Peer-reviewed Phase 1b 12-week MASLD study. n=94. Liver fat reduced up to 68.5% at 1.8 mg vs. 4.4% placebo; 55.6% of 1.8 mg group reached normal liver fat.
- [6]Altimmune, Inc.. “Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide.” 2023. LinkRCT
Company topline release for Phase 2 MOMENTUM obesity trial. n=391. Weight loss up to 15.6% at 2.4 mg over 48 weeks vs. 2.2% placebo; only 21.9% of weight lost was lean mass. Presented at ADA 84th Scientific Sessions (262-OR).
- [7]Nestor JJ, Parkes D, Feigh M, Suschak JJ, Harris MS. “Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.” Sci Rep. 2022. 12(1):6666 DOI PubMedAnimal study
Preclinical DIO-NASH proof of concept. ALT-801 (pemvidutide) compared head-to-head with semaglutide and elafibranor; superior reductions in steatosis, inflammation, and fibrosis attributed to the glucagon arm.
- [8]Nestor JJ, Zhang X, Jaw-Tsai S, et al.. “Design and characterization of a surfactant-conjugated, long-acting, balanced GLP-1/glucagon receptor dual agonist.” Pept Sci. 2021. 113(4):e24221 DOIIn vitro
Describes pemvidutide's molecular design: a balanced (1:1) GLP-1/glucagon dual agonist with the proprietary EuPort domain for albumin binding and weekly dosing. Full amino acid sequence not publicly disclosed.
- [9]
- [10]U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study
FDA safety communication on unapproved GLP-1 products. Investigational dual agonists like pemvidutide are not approved, not prescribable, and not eligible for compounding.
Medical disclaimer
Peptide Garden is an educational resource, not a medical provider. The information on this page is compiled from published research, clinical trial data, and peer-reviewed journals. It is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Pemvidutide is an investigational drug that is not FDA-approved and is not available by prescription. Breakthrough Therapy and Fast Track designations are development statuses, not approvals. Pemvidutide is only accessible through clinical trial enrollment. Always consult a qualified healthcare provider before making decisions about any medication or clinical trial participation.